MGX icon

Metagenomi

2.63 USD
--0.11
4.01%
At close Updated Oct 28, 4:00 PM EDT
Pre-market
After hours
2.67
+0.04
1.52%
1 day
-4.01%
5 days
-15.16%
1 month
14.35%
3 months
4.37%
6 months
55.62%
Year to date
-30.61%
1 year
31.5%
5 years
-74.49%
10 years
-74.49%
 

About: Metagenomi Inc is a genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived genome editing toolbox. The genome editing toolbox includes systems for making small edits such as programmable nucleases, base editors, small RNA-mediated integration systems (RIGS), as well as large gene integration systems including large template RIGS and CRISPR-associated transposases (CASTs). The company is focused on its vivo gene editing for its wholly-owned pipeline while pursuing technology out licensing for ex vivo cell therapy. Its pipeline includes product candidates aimed at addressing disorders like Hemophilia A (through MGX-001), Refractory Hypertension, Cardiovascular diseases, and Wilson's disease, among others.

Employees: 171

0
Funds holding %
of 7,501 funds
0
Analysts bullish %
of 3 analysts
Positive news %
of articles
Price charts implemented using Lightweight Charts™